Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Nueva prueba de diagnóstico in vitro para pronosticar una supervivencia superior a 15 meses en pacientes con cáncer pancreático tratados con gemcitabina

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOFR20151123002
Publicado:
08/12/2015
Caducidad:
08/12/2016
Resumen:
Una empresa francesa de biotecnología está especializada en descubrimiento de nuevos biomarcadores y desarrollo de nuevos diagnósticos. La empresa ha desarrollado una prueba de diagnóstico basada en tecnología qRT-PCR para pronosticar una supervivencia superior a 15 meses en pacientes con cáncer pancreático tratados con gemcitabina. Esta nueva prueba podría desempeñar un papel importante en la estrategia de medicina personalizada. Se buscan socios (clínicas u hospitales) para la validación clínica de esta prueba de diagnóstico in vitro.

Details

Tittle:
A new In-Vitro Diagnostic Test able to prognose a more than 15-month survival for patients suffered from Pancreatic Cancer and treated by Gemcitabine
Summary:
A French biotechnology company is specialized in the discovery of new Biomarkers and in the development of innovative Diagnostics.
They developed an In-Vitro Diagnostic test based on qRT-PCR technology that is intended to prognose a more than 15-month survival for patients diagnosed with pancreatic cancer and treated with Gemcitabine.
They are looking for partners for clinical validation of this In-Vitro Diagnostic test.
Description:
The French biotechnology company is specialized in the discovery of new Biomarkers and the development of innovative Diagnostics focused on precision medicine applications. This expertise enables the company to provide services, as well as to develop new diagnostics associated with treatments.

The Company has been developing tools and processes, and consolidating its expertise in identifying genomic/transcriptomic biomarkers for research and diagnostic applications, as well as for supporting the development of new drugs using Next-Generation Sequencing (NGS) technologies.

Pancreatic cancer represents 220,000 new cases each year and 140,000 cancer related deaths. The median survival of pancreatic cancer patients is around 3 to 6 months. Gemcitabine was the standard first-line treatment. Today, other treatments are also used like folfirinox or gemcitabine plus erlotinib or gemcitabine plus nab-paclitaxel, but the improvements in median survival duration compared to sole gemcitabine are modest. It is mandatory to develop new therapeutic strategies for this pathology with high unmet medical needs.

This French biotechnology company developed an innovative In-Vitro Diagnostic (IVD) test based on a gene blood-signature and dedicated to pancreatic cancer patients treated with gemcitabine. This new IVD test is easy to use because based on a blood sample and quantitative real-time PCR assay. The result determines the sub-population of patients more sensitive to gemcitabine treatment. This test combined to gemcitabine improves by twice the median survival rates of the sensitive responder patients.

Hence, for the patients less or not sensitive to gemcitabine, other treatments can be directly used. This innovative IVD test could play a major role in the personalized medicine strategy.

This French biotechnology company is looking for clinics or hospitals for clinical validation of its In-Vitro Diagnostic test.
Advantages and Innovations:
- A non-invasive assay,
- A new blood-based signature, based on a high throughput analysis of NGS data using a proprietary genomics platform (Big Data system dedicated to Biomarker discovery),
- An IVD test combined to gemcitabine treatment improving by twice the median survival rates of the sensitive pancreatic cancer patients.
Stage of Development:
Available for demonstration
IPs:
Patent(s) applied for but not yet granted

Partner sought

Type and Role of Partner Sought:
- Type of partner sought : Clinics, Hospitals,
- Task to be performed by the partner sought : Clinical validation

Client

Type and Size of Client:
Industry SME <= 10
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
French

Keywords

Technology Keywords:
06001003 Citología, cancerología, oncología
06001005 Diagnósticos, diagnosis
06002007 Ensayos in vitro, experimentos
06003002 Expresión genética, investigación proteómica
06001002 Investigaciones clínicas, ensayos